1. Novartis CEO Narasimhan touts blockbuster pipeline — Eli Lilly’s generic insulin to be half the price of branded counterpart — JNJ’s Invokana closes in on diabetic kidney disease approval -- See more on our front page news

    Got questions about whistleblowing?: Ask a Whistleblower Attorney
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Insulet opening

Discussion in 'Endocrinology' started by Insulet opening, Oct 2, 2018 at 12:29 AM.

Tags: Add Tags
  1. I see there is a lot of turn over here with this company. Anyone know why?
     
  2. anonymous

    anonymous Guest

    Not turnover, expansion.
     
  3. anonymous

    anonymous Guest

    high turnover, management is former Hologic people, 2 bad quarters you are done. competitor Tandem now has better product
     
  4. anonymous

    anonymous Guest

    It’s a little of both. Expanded 4x in 5 years. Also it’s a grind—weird mix between device and pharma with some DME mixed in. High growth expectations quarter over quarter.